High-throughput process development and scale-up to 2,000 L for rAAV production to address unmet patient needs

Watch the video or view the poster to learn more about:how implementing high-throughput technologies can maximize AAV process productivity and cut COGS by up to 60%;how to successfully scale up to 2000L whilst maintaining high rAAV titers; andwhich downstream purification processes to employ to ensure a high purity and full capsid ratio.Pouria Motevalian is an accomplished leader in the biopharmaceutical industry with extensive experience in developing innovative biopharmaceutical products such as viral vectors, vaccines, plasmid DNA, and multispecific antibodies. He currently oversees a team of over 30 scientists, driving significant advancements in the development and commercialization of novel viral vectors. In his prior role at Pfizer, he contributed to the development and regulatory approval of key products like Prevnar 20 and the COVID-19 mRNA vaccine.